Literature DB >> 28343148

De novo mutations in CBL causing early-onset paediatric moyamoya angiopathy.

Stéphanie Guey1, Lou Grangeon1, Francis Brunelle2,3, Françoise Bergametti1, Jeanne Amiel4,5, Stanislas Lyonnet4,5, Audrey Delaforge6, Minh Arnould1, Béatrice Desnous7, Céline Bellesme8, Dominique Hervé1,9, Jan C Schwitalla10, Markus Kraemer10, Elisabeth Tournier-Lasserve1,6, Manoelle Kossorotoff11,12.   

Abstract

BACKGROUND: Moyamoya angiopathy (MMA) is characterised by a progressive stenosis of the terminal part of the internal carotid arteries and the development of abnormal collateral deep vessels. Its pathophysiology is unknown. MMA can be the sole manifestation of the disease (moyamoya disease) or be associated with various conditions (moyamoya syndrome) including some Mendelian diseases. We aimed to investigate the genetic basis of moyamoya using a whole exome sequencing (WES) approach conducted in sporadic cases without any overt symptom suggestive of a known Mendelian moyamoya syndrome.
METHODS: A WES was performed in four unrelated early-onset moyamoya sporadic cases and their parents (trios). Exome data were analysed under dominant de novo, autosomal recessive and X-linked hypotheses. A panel of 17 additional sporadic cases with early-onset moyamoya was available for mutation recurrence analysis.
RESULTS: We identified two germline de novo mutations in CBL in two out of the four trio probands, two girls presenting with an infancy-onset severe MMA. Both mutations were predicted to alter the ubiquitin ligase activity of the CBL protein that acts as a negative regulator of the RAS pathway. These two germline CBL mutations have previously been described in association with a developmental Noonan-like syndrome and susceptibility to juvenile myelomonocytic leukaemia (JMML). Notably, the two mutated girls never developed JMML and presented only subtle signs of RASopathy that did not lead to evoke this diagnosis during follow-up.
CONCLUSIONS: These data suggest that CBL gene screening should be considered in early-onset moyamoya, even in the absence of obvious signs of RASopathy. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  CBL E3 Ubiquition Liqase; Moyamoya; Paediatrics; RASopathy; Stroke

Mesh:

Substances:

Year:  2017        PMID: 28343148     DOI: 10.1136/jmedgenet-2016-104432

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  11 in total

Review 1.  Cerebrovascular disorders associated with genetic lesions.

Authors:  Philipp Karschnia; Sayoko Nishimura; Angeliki Louvi
Journal:  Cell Mol Life Sci       Date:  2018-10-16       Impact factor: 9.261

Review 2.  Pediatric Neoplasms Presenting with Monocytosis.

Authors:  Jacob R Greenmyer; Mira Kohorst
Journal:  Curr Hematol Malig Rep       Date:  2021-02-25       Impact factor: 3.952

Review 3.  Novel Multifaceted Roles for RNF213 Protein.

Authors:  Giuliana Pollaci; Gemma Gorla; Antonella Potenza; Tatiana Carrozzini; Isabella Canavero; Anna Bersano; Laura Gatti
Journal:  Int J Mol Sci       Date:  2022-04-19       Impact factor: 6.208

Review 4.  Accessory proteins of the RAS-MAPK pathway: moving from the side line to the front line.

Authors:  Silke Pudewell; Christoph Wittich; Neda S Kazemein Jasemi; Farhad Bazgir; Mohammad R Ahmadian
Journal:  Commun Biol       Date:  2021-06-08

5.  Cerebral arteriopathy associated with heterozygous variants in the casitas B-lineage lymphoma gene.

Authors:  Ying Hong; Annette Keylock; Barbara Jensen; Thomas S Jacques; Olumide Ogunbiyi; Ebun Omoyinmi; Dawn Saunders; Andrew A Mallick; Madeleine Tooley; Ruth Newbury-Ecob; Julia Rankin; Hywel J Williams; Vijeya Ganesan; Paul A Brogan; Despina Eleftheriou
Journal:  Neurol Genet       Date:  2020-06-10

Review 6.  Role of CBL Mutations in Cancer and Non-Malignant Phenotype.

Authors:  Davide Leardini; Daria Messelodi; Edoardo Muratore; Francesco Baccelli; Salvatore N Bertuccio; Laura Anselmi; Andrea Pession; Riccardo Masetti
Journal:  Cancers (Basel)       Date:  2022-02-08       Impact factor: 6.639

7.  Pediatric Moyamoya Disease and Syndrome in Italy: A Multicenter Cohort.

Authors:  Chiara Po'; Margherita Nosadini; Marialuisa Zedde; Rosario Pascarella; Giuseppe Mirone; Domenico Cicala; Anna Rosati; Alessandra Cosi; Irene Toldo; Raffaella Colombatti; Paola Martelli; Alessandro Iodice; Patrizia Accorsi; Lucio Giordano; Salvatore Savasta; Thomas Foiadelli; Giuseppina Sanfilippo; Elvis Lafe; Federico Zappoli Thyrion; Gabriele Polonara; Serena Campa; Federico Raviglione; Barbara Scelsa; Stefania Maria Bova; Filippo Greco; Duccio Maria Cordelli; Luigi Cirillo; Francesco Toni; Valentina Baro; Francesco Causin; Anna Chiara Frigo; Agnese Suppiej; Laura Sainati; Danila Azzolina; Manuela Agostini; Elisabetta Cesaroni; Luigi De Carlo; Gabriella Di Rosa; Giacomo Esposito; Luisa Grazian; Giovanna Morini; Francesco Nicita; Francesca Felicia Operto; Dario Pruna; Paola Ragazzi; Massimo Rollo; Alberto Spalice; Pasquale Striano; Aldo Skabar; Luigi Alberto Lanterna; Andrea Carai; Carlo Efisio Marras; Renzo Manara; Stefano Sartori
Journal:  Front Pediatr       Date:  2022-05-06       Impact factor: 3.418

8.  Recalibrating vascular malformations and mechanotransduction by pharmacological intervention.

Authors:  Salim Abdelilah-Seyfried; M Luisa Iruela-Arispe; Josef M Penninger; Elisabeth Tournier-Lasserve; Miikka Vikkula; Ondine Cleaver
Journal:  J Clin Invest       Date:  2022-04-15       Impact factor: 19.456

Review 9.  Western Moyamoya Phenotype: A Scoping Review.

Authors:  Raphael Miller; Santiago R Unda; Ryan Holland; David J Altschul
Journal:  Cureus       Date:  2021-11-22

10.  The angiographic presentation of European Moyamoya angiopathy.

Authors:  Sara Pilgram-Pastor; René Chapot; Markus Kraemer
Journal:  J Neurol       Date:  2021-07-08       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.